Impact of COVID-19 on medical treatment patterns in gynecologic oncology: a MITO group survey

MITO group

doi:10.1136/ijgc-2021-002784

Impact of COVID-19 on medical treatment patterns in gynecologic oncology: a MITO group survey

MITO group

Istituto Nazionale Tumori Fondazione G. Pascale

Research output: Contribution to journal › Article › peer-review

Abstract

OBJECTIVE: COVID-19 is a global public health emergency. The increasing spread of COVID-19 presents challenges for the clinical care of patients with gynecological tumors. The Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies (MITO) performed a survey to evaluate the impact of the COVID-19 pandemic on medical treatment of gynecological cancer, with a focus on chemotherapy and oral treatment with poly(ADP)-ribose polymerase inhibitors (PARP-i).

METHODS: The survey consisted of a self-administered online questionnaire, sent via email between November 2020 and January 2021 to all members of MITO group.

RESULTS: Forty-nine centers completed the questionnaire. The majority of respondents (83%) use screening tests to determine COVID-19 status in patients who were to undergo chemotherapy or oral medications. All respondents to our survey continued cancer therapy in patients who tested negative for COVID-19 during the pandemic. Seventy-three percent of respondents declared they stopped treatment with chemotherapy or PARP-i only after a positive swab and resumed therapy when negative tests were confirmed.

CONCLUSIONS: COVID-19 positivity impacted patterns of treatment in patients diagnosed with ovarian cancer within the MITO group. Further investigations are needed to evaluate whether these modifications influence oncological clinical outcomes.

Original language	English
Pages (from-to)	1363-1368
Number of pages	6
Journal	International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Volume	31
Issue number	10
DOIs	https://doi.org/10.1136/ijgc-2021-002784
Publication status	Published - Oct 2021

Keywords

Administration, Oral
Adult
Aged
Antineoplastic Agents/therapeutic use
COVID-19/complications
COVID-19 Testing/statistics & numerical data
Female
Genital Neoplasms, Female/complications
Health Care Surveys
Health Services Accessibility/statistics & numerical data
Humans
Italy
Male
Middle Aged
Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use
Practice Patterns, Physicians'/statistics & numerical data
Withholding Treatment/statistics & numerical data

Access to Document

10.1136/ijgc-2021-002784

Cite this

@article{cbaf1f3ce633417cb6e5aaf1ca334038,

title = "Impact of COVID-19 on medical treatment patterns in gynecologic oncology: a MITO group survey",

abstract = "OBJECTIVE: COVID-19 is a global public health emergency. The increasing spread of COVID-19 presents challenges for the clinical care of patients with gynecological tumors. The Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies (MITO) performed a survey to evaluate the impact of the COVID-19 pandemic on medical treatment of gynecological cancer, with a focus on chemotherapy and oral treatment with poly(ADP)-ribose polymerase inhibitors (PARP-i).METHODS: The survey consisted of a self-administered online questionnaire, sent via email between November 2020 and January 2021 to all members of MITO group.RESULTS: Forty-nine centers completed the questionnaire. The majority of respondents (83%) use screening tests to determine COVID-19 status in patients who were to undergo chemotherapy or oral medications. All respondents to our survey continued cancer therapy in patients who tested negative for COVID-19 during the pandemic. Seventy-three percent of respondents declared they stopped treatment with chemotherapy or PARP-i only after a positive swab and resumed therapy when negative tests were confirmed.CONCLUSIONS: COVID-19 positivity impacted patterns of treatment in patients diagnosed with ovarian cancer within the MITO group. Further investigations are needed to evaluate whether these modifications influence oncological clinical outcomes.",

keywords = "Administration, Oral, Adult, Aged, Antineoplastic Agents/therapeutic use, COVID-19/complications, COVID-19 Testing/statistics & numerical data, Female, Genital Neoplasms, Female/complications, Health Care Surveys, Health Services Accessibility/statistics & numerical data, Humans, Italy, Male, Middle Aged, Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use, Practice Patterns, Physicians'/statistics & numerical data, Withholding Treatment/statistics & numerical data",

author = "{MITO group} and Raffaella Cioffi and Giulia Sabetta and Emanuela Rabaiotti and Alice Bergamini and Luca Bocciolone and Giorgio Candotti and Massimo Candiani and Giorgio Valabrega and Giorgia Mangili and Sandro Pignata",

note = "{\textcopyright} IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.",

year = "2021",

month = oct,

doi = "10.1136/ijgc-2021-002784",

language = "English",

volume = "31",

pages = "1363--1368",

journal = "International Journal of Gynecological Cancer",

issn = "1048-891X",

publisher = "Lippincott Williams and Wilkins",

number = "10",

}

TY - JOUR

T1 - Impact of COVID-19 on medical treatment patterns in gynecologic oncology

T2 - a MITO group survey

AU - MITO group

AU - Cioffi, Raffaella

AU - Sabetta, Giulia

AU - Rabaiotti, Emanuela

AU - Bergamini, Alice

AU - Bocciolone, Luca

AU - Candotti, Giorgio

AU - Candiani, Massimo

AU - Valabrega, Giorgio

AU - Mangili, Giorgia

AU - Pignata, Sandro

N1 - © IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.

PY - 2021/10

Y1 - 2021/10

N2 - OBJECTIVE: COVID-19 is a global public health emergency. The increasing spread of COVID-19 presents challenges for the clinical care of patients with gynecological tumors. The Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies (MITO) performed a survey to evaluate the impact of the COVID-19 pandemic on medical treatment of gynecological cancer, with a focus on chemotherapy and oral treatment with poly(ADP)-ribose polymerase inhibitors (PARP-i).METHODS: The survey consisted of a self-administered online questionnaire, sent via email between November 2020 and January 2021 to all members of MITO group.RESULTS: Forty-nine centers completed the questionnaire. The majority of respondents (83%) use screening tests to determine COVID-19 status in patients who were to undergo chemotherapy or oral medications. All respondents to our survey continued cancer therapy in patients who tested negative for COVID-19 during the pandemic. Seventy-three percent of respondents declared they stopped treatment with chemotherapy or PARP-i only after a positive swab and resumed therapy when negative tests were confirmed.CONCLUSIONS: COVID-19 positivity impacted patterns of treatment in patients diagnosed with ovarian cancer within the MITO group. Further investigations are needed to evaluate whether these modifications influence oncological clinical outcomes.

AB - OBJECTIVE: COVID-19 is a global public health emergency. The increasing spread of COVID-19 presents challenges for the clinical care of patients with gynecological tumors. The Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies (MITO) performed a survey to evaluate the impact of the COVID-19 pandemic on medical treatment of gynecological cancer, with a focus on chemotherapy and oral treatment with poly(ADP)-ribose polymerase inhibitors (PARP-i).METHODS: The survey consisted of a self-administered online questionnaire, sent via email between November 2020 and January 2021 to all members of MITO group.RESULTS: Forty-nine centers completed the questionnaire. The majority of respondents (83%) use screening tests to determine COVID-19 status in patients who were to undergo chemotherapy or oral medications. All respondents to our survey continued cancer therapy in patients who tested negative for COVID-19 during the pandemic. Seventy-three percent of respondents declared they stopped treatment with chemotherapy or PARP-i only after a positive swab and resumed therapy when negative tests were confirmed.CONCLUSIONS: COVID-19 positivity impacted patterns of treatment in patients diagnosed with ovarian cancer within the MITO group. Further investigations are needed to evaluate whether these modifications influence oncological clinical outcomes.

KW - Administration, Oral

KW - Adult

KW - Aged

KW - Antineoplastic Agents/therapeutic use

KW - COVID-19/complications

KW - COVID-19 Testing/statistics & numerical data

KW - Female

KW - Genital Neoplasms, Female/complications

KW - Health Care Surveys

KW - Health Services Accessibility/statistics & numerical data

KW - Humans

KW - Italy

KW - Male

KW - Middle Aged

KW - Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use

KW - Practice Patterns, Physicians'/statistics & numerical data

KW - Withholding Treatment/statistics & numerical data

U2 - 10.1136/ijgc-2021-002784

DO - 10.1136/ijgc-2021-002784

M3 - Article

C2 - 34426526

VL - 31

SP - 1363

EP - 1368

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 10

ER -

Impact of COVID-19 on medical treatment patterns in gynecologic oncology: a MITO group survey

Abstract

Keywords

Access to Document

Fingerprint

Cite this